Tonix Pharmaceuticals accelerates Mpox vaccine as WHO declares global health emergency

Proactive - Interviews for investors

Tonix Pharmaceuticals CEO Seth Lederman speaks with with Proactive's Stephen Gunnion about the company's accelerated efforts to develop a single-dose vaccine for Mpox, TNX-801, in light of the World Health Organization's declaration of a global health emergency. Lederman highlighted the vaccine's promising results in animal studies, which showed protection against lethal challenges with Clade 1 Mpox virus and prevention of skin lesions, potentially blocking forward transmission. As the threat of more lethal strains like Clade 1 emerges, Tonix is ramping up its development process, focusing on producing GMP material suitable for human trials. The vaccine, based on Tonix's RPV platform, is designed for rapid distribution and could play a critical role in managing the public health crisis. Lederman also discussed the potential risks associated with Clade 1's spread beyond Africa, stressing the need for quick and effective solutions. With a single dose, this vaccine could provide a durable defense against Mpox, akin to vaccines for smallpox. The company's efforts reflect the urgency of the situation and the importance of innovative solutions in pandemic preparedness. Visit Proactive's YouTube channel for more videos, and don't forget to give this video a like, subscribe to the channel, and enable notifications for future content. #TonixPharmaceuticals #MpoxVaccine #SethLederman #TNX801 #PublicHealth #WHO #Monkeypox #Biotech #Pharmaceuticals #PandemicPreparedness#ProactiveInvestors #InvestmentStrategy #ProactiveInvestors ##invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews